These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36503376)

  • 21. Differential approach to peripheral blood cell ratios in patients with systemic lupus erythematosus and various manifestations.
    Suszek D; Górak A; Majdan M
    Rheumatol Int; 2020 Oct; 40(10):1625-1629. PubMed ID: 32772131
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum levels of P-glycoprotein and persistence of disease activity despite treatment in patients with systemic lupus erythematosus.
    Perez-Guerrero EE; Gamez-Nava JI; Muñoz-Valle JF; Cardona-Muñoz EG; Bonilla-Lara D; Fajardo-Robledo NS; Nava-Zavala AH; Garcia-Cobian TA; Rincón-Sánchez AR; Murillo-Vazquez JD; Cardona-Müller D; Vazquez-Villegas ML; Totsuka-Sutto SE; Gonzalez-Lopez L
    Clin Exp Med; 2018 Feb; 18(1):109-117. PubMed ID: 28243944
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vitamin D Supplementation in Adolescents and Young Adults With Juvenile Systemic Lupus Erythematosus for Improvement in Disease Activity and Fatigue Scores: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Lima GL; Paupitz J; Aikawa NE; Takayama L; Bonfa E; Pereira RM
    Arthritis Care Res (Hoboken); 2016 Jan; 68(1):91-8. PubMed ID: 25988278
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity.
    Jesus D; Larosa M; Henriques C; Matos A; Zen M; Tomé P; Alves V; Costa N; Le Guern V; Iaccarino L; Costedoat-Chalumeau N; Doria A; Inês LS
    Ann Rheum Dis; 2021 Dec; 80(12):1568-1574. PubMed ID: 34407927
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Associations of the Levels of C4d-bearing Reticulocytes and High-avidity Anti-dsDNA Antibodies with Disease Activity in Systemic Lupus Erythematosus.
    Mora C; Medina-Rosas J; Santos AM; Jaimes DA; Arbeláez AM; Romero C; Cortes A; Londono J
    J Rheumatol; 2016 Sep; 43(9):1657-64. PubMed ID: 27134246
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Validation of SIMPLE Index for Lupus Disease Activity.
    Gandhi N; Arora S; Sengupta M; Sequeira W; Jolly M; Block JA
    J Clin Rheumatol; 2018 Sep; 24(6):313-318. PubMed ID: 29517552
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of disease activity, damage and quality of life in systemic lupus erythematosus: new aspects.
    Nuttall A; Isenberg DA
    Best Pract Res Clin Rheumatol; 2013 Jun; 27(3):309-18. PubMed ID: 24238688
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Assessment tools for systemic lupus erythematosus].
    Aringer M; Leuchten N
    Z Rheumatol; 2023 Jun; 82(5):361-367. PubMed ID: 37188996
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lupus headaches in childhood-onset systemic lupus erythematosus: relationship to disease activity as measured by the systemic lupus erythematosus disease activity index (SLEDAI) and disease damage.
    Brunner HI; Jones OY; Lovell DJ; Johnson AM; Alexander P; Klein-Gitelman MS
    Lupus; 2003; 12(8):600-6. PubMed ID: 12945718
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Can disease specific measures for systemic lupus erythematosus predict patients health related quality of life?
    Jolly M; Utset TO
    Lupus; 2004; 13(12):924-6. PubMed ID: 15645747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Charlson Comorbidity Index Is Related to Organ Damage in Systemic Lupus Erythematosus: Data from KORean lupus Network (KORNET) Registry.
    Kim SK; Choe JY; Lee SS
    J Rheumatol; 2017 Apr; 44(4):452-458. PubMed ID: 28298561
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High disease activity at baseline does not prevent a remission in patients with systemic lupus erythematosus.
    Formiga F; Moga I; Pac M; Mitjavila F; Rivera A; Pujol R
    Rheumatology (Oxford); 1999 Aug; 38(8):724-7. PubMed ID: 10501419
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Systemic Lupus Erythematosus Responder Index (SRI); a new SLE disease activity assessment.
    Luijten KM; Tekstra J; Bijlsma JW; Bijl M
    Autoimmun Rev; 2012 Mar; 11(5):326-9. PubMed ID: 21958603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. QRISK3-based analysis of cardiovascular risk factors in patients with long-term but well-controlled systemic lupus erythematosus.
    Wang SL; Li W; Li TF; Liang X; Yan YL; Liu SY
    Am J Transl Res; 2022; 14(5):3247-3260. PubMed ID: 35702101
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CXCL13 is an activity marker for systemic, but not cutaneous lupus erythematosus: a longitudinal cohort study.
    Niederkorn A; Frühauf J; Schwantzer G; Wutte N; Painsi C; Werner S; Stradner M; Berghold A; Hermann J; Aberer E
    Arch Dermatol Res; 2018 Aug; 310(6):485-493. PubMed ID: 29728857
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The chronic damage in systemic lupus erythematosus is driven by flares, glucocorticoids and antiphospholipid antibodies: results from a monocentric cohort.
    Conti F; Ceccarelli F; Perricone C; Leccese I; Massaro L; Pacucci VA; Truglia S; Miranda F; Spinelli FR; Alessandri C; Valesini G
    Lupus; 2016 Jun; 25(7):719-26. PubMed ID: 26821965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of Serum Interleukin (IL)-1β and IL-18 in Systemic Lupus Erythematosus.
    Mende R; Vincent FB; Kandane-Rathnayake R; Koelmeyer R; Lin E; Chang J; Hoi AY; Morand EF; Harris J; Lang T
    Front Immunol; 2018; 9():1250. PubMed ID: 29930551
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the responsiveness of lupus disease activity measures to changes in systemic lupus erythematosus activity relevant to patients and physicians.
    Chang E; Abrahamowicz M; Ferland D; Fortin PR;
    J Clin Epidemiol; 2002 May; 55(5):488-97. PubMed ID: 12007552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cross-cultural validation of a disease-specific patient-reported outcome measure for systemic lupus erythematosus in Canada.
    Bourré-Tessier J; Clarke AE; Mikolaitis-Preuss RA; Kosinski M; Bernatsky S; Block JA; Jolly M
    J Rheumatol; 2013 Aug; 40(8):1327-33. PubMed ID: 23772082
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus.
    Groot N; Shaikhani D; Teng YKO; de Leeuw K; Bijl M; Dolhain RJEM; Zirkzee E; Fritsch-Stork R; Bultink IEM; Kamphuis S
    Arthritis Rheumatol; 2019 Feb; 71(2):290-301. PubMed ID: 30152151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.